Piramal Pharma Limited has officially notified stock exchanges about its upcoming board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company issued the intimation under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting will focus on considering and approving the unaudited financial results for both standalone and consolidated operations. The meeting covers the financial performance for the quarter and nine months ended December 31, 2025.

Trading Window Closure

In accordance with regulatory requirements, Piramal Pharma Limited has implemented a trading window closure for company securities. The trading window, which commenced closure on January 1, 2026, will remain closed until January 30, 2026, both days inclusive.

Regulatory Compliance

The company has formally notified both major Indian stock exchanges about the scheduled board meeting. BSE Limited, where the company trades under scrip code 543635, and National Stock Exchange of India Limited, where it trades under the symbol PPLPHARMA, have been informed through official communication dated January 16, 2026.

Company Secretary Tanya Sanish signed the official intimation, ensuring compliance with SEBI Listing Regulations. The notification follows standard corporate governance practices for listed pharmaceutical companies in India, providing investors and stakeholders with advance notice of material financial disclosures.

Piramal Pharma has received a US FDA Form-483 for its Lexington facility following a Good Manufacturing Practices (GMP) inspection. The pharmaceutical company disclosed that the inspection identified four regulatory observations that will be classified as VAI (Voluntary Action Indicated).

FDA Inspection Details

The US FDA conducted a comprehensive GMP inspection at Piramal Pharma's Lexington facility in Kentucky, USA. At the conclusion of the inspection, the regulatory authority issued Form-483 documenting four observations related to enhancement in procedures.

Company Response and Compliance

Piramal Pharma has confirmed that it is preparing a detailed response to address all observations identified during the inspection. The company stated it will submit this comprehensive response to the US FDA within the stipulated regulatory timelines. The observations are specifically related to procedural enhancements rather than critical manufacturing deficiencies.

Regulatory Classification

The VAI (Voluntary Action Indicated) classification indicates that the FDA found objectionable conditions during the inspection, but the agency is not prepared to take or recommend any administrative or regulatory action. This classification is less severe than an Official Action Indicated (OAI) status, which would require more immediate and stringent corrective measures.

Commitment to Standards

The company emphasized its commitment to maintaining the highest standards of compliance and stated it will work closely with the FDA to comprehensively address all observations. This approach demonstrates Piramal Pharma's dedication to regulatory compliance and quality manufacturing standards at its US operations.